Tech Company Financing Transactions
Refuge Biotechnologies Funding Round
3SBio, Sequoia Capital and 3E Bioventures participated in a $25 million Series B venture round for Refuge Biotechnologies. The financing round was announced on 5/3/2018.
Transaction Overview
Company Name
Announced On
5/3/2018
Transaction Type
Venture Equity
Amount
$25,000,000
Round
Series B
Investors
3SBio (Lead Investor) (Zhenping Zhu)
Sequoia Capital (Lead Investor) (Trency Gu)
Proceeds Purpose
The funds from the Series B will support advancement of cell therapies developed with Refuge's receptor-dCas platform, which utilizes a mutated or dead Cas9 (dCas) as a targeting mechanism to enable precision CRISPR activation (CRISPRa) and CRISPR interference (CRISPRi).
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
1505 Adams Dr. D
Menlo Park, CA 94025
USA
Menlo Park, CA 94025
USA
Phone
Undisclosed
Website
Email Address
Not Recorded
Overview
Refuge is leveraging gene engineering technologies known as CRISPR interference (CRISPRi) and CRISPR activation (CRISPRa) to develop therapeutic cells that are programmed to make decisions inside the patient's body.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Bing Wang
Chief Scientific Officer
Francesco Marincola
Co-Founder
David Parkinson
Co-Founder
Stanley Qi
VP - Finance
Ida Louie
VP - R & D
Frank Liang
Browse more venture capital transactions:
Prev: 5/3/2018: C2RO venture capital transaction
Next: 5/3/2018: Upbound venture capital transaction
Share this article
Where The Data Comes From
We do our best to record every notable VC transaction. All VC database entries on this site are sourced from news reports and company announcements. The data is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs